# US 2004/0082606 A1 · Excitatory amino acid receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082606 A1
- Document ID: US20040082606A1
- Status: Published application
- Kind: A1
- Application number: 10/450,458
- Filed: 2003-06-13
- Published: 2004-04-29
- Earliest claimed: 2003-06-13
- Inventors: Vien Van Khau; Michael Edward Letourneau; Michael John Martinelli
- Web page: https://patentgrep.com/patent/US20040082606A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel pharmaceutically acceptable salts of the compounds of Formula (I) and Formula (Ia), as well as methods for using the pharmaceutically acceptable salts, and also provides processes for making compounds of Formula (I) and Formula (Ia), or the pharmaceutically acceptable salts thereof. Compounds of formula (I) and formula (Ia) are useful for the treatment of neurological disorders, especially migraine.

## Claims

### Claim 1

A pharmaceutically acceptable salt of a compound of the formula:
30
or a prodrug thereof, wherein the pharmaceutically acceptable salt is selected from the group consisting of the d-(−)-mandelic acid salt or the 1,5-naphthalene disulfonic acid salt.

### Claim 2 (depends on 1)

The pharmaceutically acceptable salt according to claim 1, wherein the salt is the D-(−)-mandelic acid salt.

### Claim 3 (depends on 1)

The pharmaceutically acceptable salt according to claim 1, wherein the salt is the 1,5-naphthalene disulfonic acid salt.

### Claim 4

A compound which is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid.D-(−)-mandelic acid.

### Claim 5

A compound which is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3carboxylic acid.1,5-naphthalene disulfonic acid.

### Claim 6

A pharmaceutically acceptable salt of a compound of the formula:
31
wherein
R1 and R2 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R1 and R2 are other than hydrogen;
wherein the pharmaceutically acceptable salt is selected from the group consisting of the D-(−)-mandelic acid salt or the 1,5-naphthalene disulfonic acid salt.

### Claim 7 (depends on 6)

The pharmaceutically acceptable salt according to claim 6, wherein R1 and R2 are each independently (C1-C20)alkyl.

### Claim 8 (depends on 7)

The pharmaceutically acceptable salt according to claim 7, wherein R1 and R2 are each independently (C1-C6)alkyl.

### Claim 9 (depends on 8)

The pharmaceutically acceptable salt according to claim 8, wherein the salt is the D-(−)-mandelic acid salt.

### Claim 10 (depends on 8)

The pharmaceutically acceptable salt according to claim 8, wherein the salt is the 1,5-naphthalene disulfonic acid salt.

### Claim 11

A compound which is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.D-(−)-mandelic acid.

### Claim 12

A compound which is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.1,5-naphthalene disulfonic acid.

### Claim 13 (depends on 1)

A method of treating a neurological disorder or neurodegenerative disease comprising administering to a patient in need thereof, an effective amount of a pharmaceutically acceptable salt according to claim 1.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the neurological disorder is migraine.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the pharmaceutically acceptable salt is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid.D-(−)-mandelic acid.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the pharmaceutically acceptable salt is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.1,5-naphthalene disulfonic acid.

### Claim 17 (depends on 6)

A method of treating a neurological disorder or neurodegenerative disease comprising administering to a patient in need thereof, an effective amount of a pharmaceutically acceptable salt according to claim 6.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the neurological disorder is migraine.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the pharmaceutically acceptable salt is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid.D-(−)-mandelic acid.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the pharmaceutically acceptable salt is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3carboxylate.1,5-naphthalene disulfonic acid.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising an effective amount of the pharmaceutically acceptable salt according to claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 22 (depends on 6)

A pharmaceutical composition comprising an effective amount of the pharmaceutically acceptable salt according to claim 6, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 23 (depends on 1)

The use of a compound according to claim 1 for the manufacture of a medicament for the treatment of migraine.

### Claim 24 (depends on 6)

The use of a compound according to claim 6 for the manufacture of a medicament for the treatment of migraine.

### Claim 25 (depends on 1)

The use of a compound according to claim 1 for the treatment of migraine.

### Claim 26 (depends on 6)

The use of a compound according to claim 6 for the treatment of migraine.

### Claim 27

A process for preparing a compound of the formula:
32
wherein
R1 and R2 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R1 and R2 are other than hydrogen,
comprising combining a compound of structure (2)
33
wherein R2 is as defined above, Pg is a suitable nitrogen protecting group, and LgO is a suitable leaving group, with a suitable base in a suitable solvent, followed by addition of a compound of structure (3)
34
wherein R1 is as defined above, followed by oxidation to a compound of structure (5)
35
followed by halogenation and removal of the nitrogen protecting group.
